

Growth Panel

Matt McCall – REV Group (REVG) and Traeger (COOK)

REV Group is a leading provider of fire and emergency, commercial, and recreation vehicles.

Matt likes this stock because REVG meets his criteria:

1. It's in a megatrend. The growth in electric vehicles will be insane. EVs are going to be everywhere.
2. Company is growing faster than its peers.
3. The stock is cheap.

REV earnings are increasing 35% annually and the stock trades for 0.35 times sales and 9.4 times earnings.

Traeger (COOK) – This is tech when it comes to grilling. Huge opportunity and the brand is starting to become very popular.

Tom Carroll – MariMed (MRMD)

MariMed is an up-and-coming cannabis company.

First, cannabis stocks are insanely cheap. They trade for 3.7 times sales.

MariMed has not yet listed on any exchange -- it's on OTC. MariMed is looking to list in Canada and that would open the door to investors to get into this stock.

It's got a great management team. Sales have more than doubled this year. Plus, EBITDA is positive and the balance sheet is solid.

It will grow by expanding to different states and also through M&A. MariMed is also a candidate to be acquired since many smaller, regional players have been being bought up in recent months.

Mike DiBiase – Olo (OLO)

Mike's pick last year was Designer Brands (DBI) – and is up 125%.

He also picked Asana (ASAN) – a software company that is up 375%.

This year's pick, Olo, is a digital ordering and delivery software for restaurants. It manages the entire digital business (mobile, web, text, kiosk).

Olo has 400 customer brands like Shake Shack, Applebee's, IHOP, and Subway. Still has a huge potential for growth as there are many other big chain restaurants as possible customers.

Olo is a SaaS company and IPO'd in March 2021.

SaaS companies make for great investments. They average 80% annualized returns since 2004.

Olo has fantastic numbers. It grew 94% last year, has gross margins of 80%, and it is already profitable.

Like most SaaS stocks, Olo is expensive. EV to next year's sales is 19x. Still, like Asana, the opportunity for growth is incredible and valuation should not be a reason to not buy.

Eric Wade – Covered calls on bitcoin

Eric recommends covered calls on bitcoin. If you sell covered calls on bitcoin, you could earn a yield of around 50%. The yield will vary depending on what bitcoin trades for.

You can go to ribbon.finance in order to do this. Eric also recommends taking your time getting into this trade.

Eric says you can check out his weekly updates in Crypto Capital if you want to learn more about how to do this.

Matt Weinschenk – AbCellera Biologics (ABCL)

AbCellera is a drug-discovery platform. It's not a pharmaceutical company itself. Rather, it helps pharma companies identify potential drugs, specifically antibodies.

AbCellera can take antibody development from the first sample all the way to finding an antibody that can work as a drug. Its process starts with proprietary "microfluidics" that allow it to separate cells from a sample, and it goes on to artificial intelligence ("AI") computer-vision technology that can look at proteins and judge whether they may be a viable antibody.

This process saved lives in 2020.

AbCellera knew that the urgency of COVID-19 would make a great use of its technology, and it entered a partnership with Eli Lilly (LLY) to develop a SARS-CoV-2 antibody.

In February 2020, AbCellera received a sample from one of the first U.S. patients to get COVID-19. That patient is our new Henrietta Lacks... because his or her antibodies ended up treating hundreds of thousands of people.

AbCellera used its advanced microfluidics system to isolate and screen 5.8 million cells from that sample. This is not easy. But AbCellera's technology allows

researchers to use a device the size of a credit card with more than a half-million miniature chambers to separate cells.

Then the company identified 2,200 candidates that looked like spike-protein antibodies and eventually got 500 monoclonal antibodies out of that.

We're already down to less than 0.008% of the cells from the original sample. But at 500 candidates, that's still too many drugs to test.

That's where AbCellera's image-recognition AI came in. The system analyzed those 500 candidates and isolated 24 that were worthy of human testing. Those candidates got sent off to Eli Lilly.

The challenge is that AbCellera may be a more than a one-year story. It's a great long-term buy because the growth could be explosive. Matt thinks this stock could easily be a double or triple winner, or higher.